TAGS: Sustainability / Natural Cosmetics
Skin Care
Willow Biosciences Inc. has signed a multi-year supply agreement with Cellular Goods PLC, a U.K. based provider of consumer products based on biosynthetically made cannabinoids.
Willow will supply Cellular Goods with its proprietary, ultra-pure, biosynthetically produced, cannabigerol ("Willow CBG") to be used in Cellular Goods' cannabinoid-based skin care products to be launched in autumn of 2021.
Ideal Ingredient for Cosmetics
In April 2021, Willow announced that it has completed a series of studies with its development partner, Signum Biosciences, Inc., that demonstrate the safety and anti-inflammatory, anti-aging, and antimicrobial properties of Willow CBG on human skin. These results, coupled with the sustainable and safe manufacturing nature of Willow's manufacturing process, make Willow CBG an ideal core ingredient for cosmetics in the evolving regulatory landscape of the United Kingdom.
"
Successful products start with the best ingredients and being able to source consistent, highly-pure cannabinoids via cellular agriculture from a trusted provider like Willow is essential to our business. CBG is the most promising cannabinoid for skincare applications and we believe it will become a must have upgrade to people's daily routines. Cellular Goods will be the first to bring a range to market in the United Kingdom built on our core principles of delivering efficacy-led and research-backed consumer cannabinoid products,” said Alexis Abraham, Cellular Goods chief executive officer.
EU Declared CBG as Safe for Use
In May 2021, the European Commission declared that CBG had been added to the European Union cosmetic ingredients database (named "CosIng"), approving the compound as safe for use in personal care and cosmetics products. European manufacturers of personal care and cosmetics products can now use CBG in their products with the approval of a major market regulator for trade in the European Union.
"
We are very excited to announce our first commercial supply agreement for CBG. In just over two years we have gone from proof of concept in the lab to commercial scale up and sales of our first cannabinoid which will be slated for use in a consumer product. Cellular Goods are at the forefront, developing premium consumer cannabinoid products in the United Kingdom and we are thrilled to be supplying them with our ultra-pure, biosynthetically made CBG,” said Trevor Peters, Willow's president & chief executive officer.
Source: Willow Biosciences